• Publications
  • Influence
DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent.
The DNA-binding profile of a novel, trinuclear platinum Phase I clinical agent (BBR3464) is summarized. The structure of BBR3464 is best described as two trans-[PtCl(NH3)2] units linked by aExpand
  • 169
  • 6
Double‐check probing of DNA bending and unwinding by XPA–RPA: an architectural function in DNA repair
The multiprotein factor composed of XPA and replication protein A (RPA) is an essential subunit of the mammalian nucleotide excision repair system. Although XPA–RPA has been implicated in damageExpand
  • 172
  • 6
DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues.
  • V. Brabec, M. Leng
  • Chemistry, Medicine
  • Proceedings of the National Academy of Sciences…
  • 1 June 1993
Bases in the opposite strands of DNA cross-linked by clinically ineffective trans-diamminedichloroplatinum(II) (trans-[Pt(NH3)2Cl2]) have been identified by means of three experimental approaches.Expand
  • 209
  • 5
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Transition-metal-based compounds constitute a discrete class of chemotherapeutics, widely used in the clinic as antitumor and antiviral agents. Examples of established antitumor metallodrugs,Expand
  • 292
  • 5
Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs.
The importance of platinum drugs in cancer chemotherapy is underscored by the clinical success of cisplatin [cis-diamminedichloroplatinum(II)] and its analogues and by clinical trials of other, lessExpand
  • 285
  • 4
DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair.
  • V. Brabec
  • Biology, Medicine
  • Progress in nucleic acid research and molecular…
  • 2002
The development of metal-based antitumor drugs has been stimulated by the clinical success of cis-diamminedichloroplatinum(II) (cisplatin) and its analogs and by the clinical trials of other platinumExpand
  • 206
  • 4
Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog.
Downstream processes that discriminate between DNA adducts of a third generation platinum antitumor drug oxaliplatin and conventional cisplatin are believed to be responsible for the differences inExpand
  • 56
  • 4
  • PDF
Molecular aspects of resistance to antitumor platinum drugs.
The processes by which cells develop resistance to antitumor platinum drugs have been the subject of intense research because resistance is a major obstacle for the clinical use of this class ofExpand
  • 136
  • 3
Mechanism of the formation of DNA–protein cross-links by antitumor cisplatin
DNA–protein cross-links are formed by various DNA-damaging agents including antitumor platinum drugs. The natures of these ternary DNA–Pt–protein complexes (DPCLs) can be inferred, yet much remainsExpand
  • 112
  • 3
  • PDF
Recognition of major DNA adducts of enantiomeric cisplatin analogs by HMG box proteins and nucleotide excision repair of these adducts.
We examined HMG domain protein recognition of major 1,2-GG intrastrand DNA crosslinks, formed by two bifunctional enantiomeric analogs of antitumor cis-diamminedichloroplatinum(II) (cisplatin), andExpand
  • 62
  • 3